NATIONAL CLINICAL ONCOLOGY HUB · GLOBAL LEADER IN GASTROINTESTINAL CANCERS & MELANOMA
Peking University Cancer Hospital (Beijing Cancer Hospital)
Founded in 1976, Peking University Cancer Hospital (Beijing Cancer Hospital / Beijing Institute for Cancer Research) is one of China’s most celebrated academic specialized cancer centers. Affiliated with Peking University, the hospital is internationally recognized as the foremost authority in digestive tract oncology, melanoma, and soft tissue sarcomas.
Under the leadership of past International Gastric Cancer Association (IGCA) President Prof. Ji Jiafu and Chinese Melanoma Society Chair Prof. Guo Jun, PKU Cancer Hospital sets international benchmarks for D2/D2+ radical gastrectomy, comprehensive colorectal liver metastasis MDTs, and targeted/cellular therapies for mucosal and acral melanoma.
FOUR CLINICAL EXCELLENCE PILLARS
Core Gastrointestinal & Melanoma Capabilities
PKU Cancer Hospital integrates world-leading surgical oncology techniques with cutting-edge targeted, immune, and cellular therapies.
Gastric Cancer Center
Standardization of laparoscopic D2/D2+ radical gastrectomy, perioperative immunotherapy, and HIPEC for peritoneal dissemination.
Melanoma & Sarcoma
Global leadership in treating mucosal and acral melanoma using targeted kinase inhibitors, checkpoint blockade, and TIL therapy.
Colorectal Surgery MDT
Laparoscopic and robotic total mesorectal excision (TME) combined with multidisciplinary liver metastasectomy.
Interventional Oncology
CT- and ultrasound-guided radiofrequency, microwave, and cryoablation for complex hepatic and lung metastases.
WORLD-RENOWNED DIGESTIVE ONCOLOGY & MELANOMA MASTERS
Academic Faculty & Department Leadership
Steered by past presidents of international surgical societies and leaders of national oncology committees.
Prof. Ji Jiafu, MD, PhD
World authority in gastric surgical oncology who established international clinical guidelines for standardized D2 lymphadenectomy and perioperative therapy for gastric cancer.
Prof. Guo Jun, MD, PhD
Pioneer in targeted and immunotherapy combinations for acral and mucosal melanoma, conditions prevalent in Asia. Prof. Guo leads international clinical trials defining standard-of-care systemic regimens.
CASE INTAKE & SPECIALIST TRIAGE
Initiate Your Case Review with PKU Cancer Hospital
Submit your contact details, confirmed diagnosis, and main question below. You do not need to upload any medical files at this stage. Our clinical coordinator will contact you directly within 24–48 hours to discuss potential Peking University Cancer Hospital pathways in China and assist you in gathering the specific medical records needed for expert hospital review.
PATIENT INQUIRIES
Frequently Asked Questions About PKU Cancer Hospital
Key clinical, logistical, and technical facts regarding international admissions, surgical evaluations, advanced technology access, and personalized care coordination at PKU Cancer Hospital.
PKU Cancer Hospital is the world leader in mucosal and acral melanoma. Under Prof. Guo Jun, the hospital pioneered combination protocols combining VEGFR tyrosine kinase inhibitors (e.g., axitinib) with anti-PD-1 antibodies, as well as tumor-infiltrating lymphocyte (TIL) cellular therapies.
Under Prof. Ji Jiafu’s standardized surgical techniques, patients undergoing curative D2 gastrectomy achieve overall 5-year survival rates exceeding 65%, with major postoperative complication rates well below international averages.
Yes. Patients with localized peritoneal dissemination are evaluated for conversion systemic immunochemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
Through our fast-track international channel, pre-operative staging and multidisciplinary review are completed within 48 to 72 hours, with surgery typically performed within 4 to 6 business days of admission.
MODERN CLINICAL INFRASTRUCTURE
Strategic Multi-Campus Setup & International Transit
Modern clinical hubs designed for seamless aeromedical transport, multidisciplinary conferences, and dedicated international inpatient care.
PKU Cancer Haidian Campus
52 Fucheng Road, Haidian District, Beijing
Primary clinical hospital housing surgical operating theaters, digestive oncology wards, and VIP inpatient suites.
Beijing Institute for Cancer Research
Haidian Medical Science Park, Beijing
Dedicated molecular genetics, translational cancer research, and Phase I clinical trial center.